Last reviewed 2026-04-22 · How we verify

Dexamethasone+Tropisetron

Dexamethasone suppresses inflammatory and immune responses while tropisetron blocks serotonin receptors to prevent nausea and vomiting.

Dexamethasone suppresses inflammatory and immune responses while tropisetron blocks serotonin receptors to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in cancer patients.

At a glance

Mechanism of action

Dexamethasone is a corticosteroid that reduces inflammation and immune activation by binding glucocorticoid receptors, while tropisetron is a 5-HT3 receptor antagonist that prevents chemotherapy-induced nausea and vomiting (CINV) by blocking serotonin signaling in the chemoreceptor trigger zone. This combination is used to manage side effects in cancer patients undergoing chemotherapy.

Approved indications

• Chemotherapy-induced nausea and vomiting (CINV) prevention in cancer patients

Common side effects

• Headache
• Constipation
• Insomnia
• Hyperglycemia
• Dizziness

Key clinical trials

• Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen (PHASE3)
• Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
• Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (PHASE4)
• Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
• Anti-emetic Prophylaxis With or Without Dexamethasone (PHASE3)
• Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP (NA)
• High-dose Opioid Versus Opioid-sparing Anaesthesia in Cardiac Surgery (NA)
• Efficacy of Three Antiemetics in Preventing Nausea and Vomiting (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.